OverviewSuggest Edit

Celsion Corporation is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Our lead product candidate is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 trial combined with RFA for the treatment of hepatocellular carcinoma. It is also in a phase 2 study for the treatment of recurrent chest wall breast cancer. Second in our pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer.
Celsion has 3 platform technologies providing the basis for the development of a range of therapeutics for difficult-to-treat forms of cancers. With these technologies we are working to develop and commercialize more efficient, effective, and targeted oncology therapies, maximizing efficacy while minimizing side effects common to cancer treatments.

TypePublic
Founded1982
HQTrenton, US
Websitecelsion.com
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)21
Revenue (FY, 2017)$500 K
Share Price (Mar 2019)$2.3 (-6%)

Key People/Management at Celsion

Michael H. Tardugno

Michael H. Tardugno

President and Chief Executive Officer
Jeffrey W. Church

Jeffrey W. Church

Senior Vice President, Corporate Business Strategy and Investor Relations
Nicholas Borys

Nicholas Borys

Vice President and Chief Medical Officer
Show more

Celsion Office Locations

Celsion has an office in Trenton
Trenton, US (HQ)
997 Lenox Dr
Show all (1)
Report incorrect company information

Celsion Financials and Metrics

Celsion Revenue

Celsion's revenue was reported to be $500 k in FY, 2017
USD

Revenue (Q2, 2018)

125.0k

Net income (Q2, 2018)

(8.2m)

EBIT (Q2, 2018)

(8.0m)

Market capitalization (15-Mar-2019)

42.3m

Closing stock price (15-Mar-2019)

2.3

Cash (30-Jun-2018)

12.8m
Celsion's current market capitalization is $42.3 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

500.0k500.0k500.0k500.0k

General and administrative expense

6.5m6.7m6.5m5.9m

R&D expense

9.4m14.7m14.6m13.1m

Operating expense total

15.9m21.3m21.1m19.0m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

125.0k125.0k125.0k125.0k125.0k125.0k125.0k125.0k125.0k125.0k125.0k

General and administrative expense

2.3m2.0m2.0m1.8m1.5m1.9m1.5m1.5m1.5m1.6m1.2m1.7m3.5m

R&D expense

3.2m4.6m4.5m3.6m2.9m3.4m3.3m4.2m3.5m3.0m3.3m2.7m4.6m

Operating expense total

6.5m6.8m6.5m5.4m4.4m5.3m4.9m5.7m4.9m4.7m4.5m4.4m8.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.7m12.7m9.3m2.6m11.4m

Accounts Receivable

Inventories

Current Assets

4.5m24.3m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

9.6m4.6m7.6m12.0m7.6m14.3m12.3m4.2m4.5m3.6m2.7m2.3m12.8m

Current Assets

50.5m44.5m30.7m31.5m24.8m15.0m9.0m4.6m3.7m2.8m20.9m26.3m

PP&E

851.0k1.0m954.7k756.8k657.6k543.8k370.3k256.6k142.9k(175.1k)192.8k

Goodwill

1.9m2.0m2.0m2.0m2.0m2.0m2.0m2.0m2.0m2.0m2.0m2.0m2.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.3m)(25.5m)(22.5m)(22.1m)(20.4m)

Depreciation and Amortization

339.2k369.3k425.0k1.0m553.0k

Inventories

77.5k246.4k

Accounts Payable

(887.3k)1.8m(859.2k)48.8k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(12.1m)(19.0m)(7.0m)(5.7m)(16.9m)(5.7m)(10.2m)(16.7m)(5.2m)(10.1m)(15.7m)(4.5m)(12.7m)

Depreciation and Amortization

174.8k262.1k329.6k121.9k243.8k365.6k170.5k341.1k511.6k87.2k174.3k

Accounts Payable

1.9m2.7m65.3k(118.9k)(195.7k)1.2m665.6k(72.8k)(565.9k)35.8k

Cash From Operating Activities

(16.9m)
USDY, 2018

Financial Leverage

2.6 x
Show all financial metrics
Report incorrect company information

Celsion News and Updates

Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAWRENCEVILLE, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the “Induce…

Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference

LAWRENCEVILLE, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice President and Chief Financial Officer, will present at NobleConXV - Noble Capital Markets’ 15th Annual Inve…

Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium

Data to be Highlighted During Oral Session on March 2, 2019
Show more
Report incorrect company information

Celsion Blogs

Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

100% Objective Response Rates and 88% Complete (R0) Resection Rates in Highest Dose Cohorts GEN-1 Intraperitoneally Delivered Durable Local Levels of Pro-Immune IL-12 and Related Cytokines Dose Dependent Reduction in Immunosuppressive Biomarkers Suggest Positive Effect on Tumor Microenvironment

Celsion Announces Publication of ThermoDox® Study Results in Radiology

Publication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox ® and Non-Invasive, Focused Ultrasound University of Oxford’s Findings Provide Additional Independent Evidence of ThermoDox’s Unique and Highly Effective Anti-Cancer Mechanism LAWRENCEVILLE, N.J , Jan.

Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer

Current Combined, Blinded Progression-Free Survival (PFS) Rate for Both Treatment Arms Reaches 21.2 Months Compared to 19.8 Months for the Intent-To-Treat (ITT) Population in the HEAT Study Post-Hoc Analysis Subgroup Current Combined, Blinded Overall Survival (OS) Rate for Both Treat Arms is

Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations

Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations Content Import Mon, 09/17/2018 - 08:33 Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations Sep 17, 2018 This release …

Celsion Corporation Reports Second Quarter 2018 Financial Results and Provides Business Update

Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance                Company to Hold Conference Call on Tuesday, August 14, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , Aug.

Celsion Frequently Asked Questions

  • When was Celsion founded?

    Celsion was founded in 1982.

  • Who are Celsion key executives?

    Celsion's key executives are Michael H. Tardugno, Jeffrey W. Church and Nicholas Borys.

  • How many employees does Celsion have?

    Celsion has 21 employees.

  • What is Celsion revenue?

    Latest Celsion annual revenue is $500 k.

  • What is Celsion revenue per employee?

    Latest Celsion revenue per employee is $23.8 k.

  • Who are Celsion competitors?

    Competitors of Celsion include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Celsion headquarters?

    Celsion headquarters is located at 997 Lenox Dr, Trenton.

  • Where are Celsion offices?

    Celsion has an office in Trenton.

  • How many offices does Celsion have?

    Celsion has 1 office.